Literature DB >> 9428731

The amyloidogenic potential of transthyretin variants correlates with their tendency to aggregate in solution.

A Quintas1, M J Saraiva, R M Brito.   

Abstract

Amyloid fibril formation and deposition are the basis for a wide range of diseases, including spongiform encephalopathies, Alzheimer's and familial amyloidotic polyneuropathies. However, the molecular mechanisms of amyloid formation are still poorly characterised. In certain forms of familial amyloidotic polyneuropathy (FAP), the amyloid fibrils are mostly constituted by variants of transthyretin (TTR). V30M-TTR is the most frequent variant, and L55P-TTR is the variant associated with the most aggressive form of amyloidosis. Here, we report gel filtration chromatography experiments to characterise the aggregation states of WT-, V30M-, L55P-TTR and a non-amyloidogenic variant, T119M-TTR, in solution, at nearly physiological pH. These studies show that all four protein tetramers dissociate to monomer upon dilution, in the submicromolar range, at pH 7.0. The amyloidogenic proteins V30M- and L55P-TTR show a complex equilibrium between monomers, tetramers and high molecular weight aggregate species. These aggregates dissociate directly to monomer upon dilution. This study shows that the tendency to form aggregates among the four studied proteins correlates with their known amyloidogenic potential. Thus, the amyloidogenic mutations could perturb the structure and/or stability of the monomeric species leading initially to the formation of soluble aggregates and at a later stage to insoluble amyloid fibrils.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9428731     DOI: 10.1016/s0014-5793(97)01398-7

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  22 in total

1.  Mass spectrometric immunoassay for quantitative determination of transthyretin and its variants.

Authors:  Olgica Trenchevska; Elena Kamcheva; Dobrin Nedelkov
Journal:  Proteomics       Date:  2011-08-09       Impact factor: 3.984

2.  Inhibition of curli assembly and Escherichia coli biofilm formation by the human systemic amyloid precursor transthyretin.

Authors:  Neha Jain; Jörgen Ådén; Kanna Nagamatsu; Margery L Evans; Xinyi Li; Brennan McMichael; Magdalena I Ivanova; Fredrik Almqvist; Joel N Buxbaum; Matthew R Chapman
Journal:  Proc Natl Acad Sci U S A       Date:  2017-10-30       Impact factor: 11.205

3.  Potent kinetic stabilizers that prevent transthyretin-mediated cardiomyocyte proteotoxicity.

Authors:  Mamoun M Alhamadsheh; Stephen Connelly; Ahryon Cho; Natàlia Reixach; Evan T Powers; Dorothy W Pan; Ian A Wilson; Jeffery W Kelly; Isabella A Graef
Journal:  Sci Transl Med       Date:  2011-08-24       Impact factor: 17.956

4.  Designing transthyretin mutants affecting tetrameric structure: implications in amyloidogenicity.

Authors:  C Redondo; A M Damas; M J Saraiva
Journal:  Biochem J       Date:  2000-05-15       Impact factor: 3.857

5.  Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis.

Authors:  Nora S Green; Ted R Foss; Jeffery W Kelly
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-29       Impact factor: 11.205

6.  The preaggregated state of an amyloidogenic protein: hydrostatic pressure converts native transthyretin into the amyloidogenic state.

Authors:  A D Ferrão-Gonzales; S O Souto; J L Silva; D Foguel
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

7.  Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative.

Authors:  Maria Rosário Almeida; Bárbara Macedo; Isabel Cardoso; Isabel Alves; Gregorio Valencia; Gemma Arsequell; Antoni Planas; Maria João Saraiva
Journal:  Biochem J       Date:  2004-07-15       Impact factor: 3.857

8.  Amyloidogenic potential of transthyretin variants: insights from structural and computational analyses.

Authors:  Laura Cendron; Antonio Trovato; Flavio Seno; Claudia Folli; Beatrice Alfieri; Giuseppe Zanotti; Rodolfo Berni
Journal:  J Biol Chem       Date:  2009-07-14       Impact factor: 5.157

9.  Potentially amyloidogenic conformational intermediates populate the unfolding landscape of transthyretin: insights from molecular dynamics simulations.

Authors:  J Rui Rodrigues; Carlos J V Simões; Cândida G Silva; Rui M M Brito
Journal:  Protein Sci       Date:  2010-02       Impact factor: 6.725

10.  Specific pathogen free conditions prevent transthyretin amyloidosis in mouse models.

Authors:  Seiya Inoue; Mika Ohta; Zhenghua Li; Gang Zhao; Yutaka Takaoka; Naomi Sakashita; Kazuhisa Miyakawa; Koji Takada; Hajime Tei; Misao Suzuki; Michio Masuoka; Yoshiyuki Sakaki; Kiyoshi Takahashi; Ken-Ichi Yamamura
Journal:  Transgenic Res       Date:  2008-03-21       Impact factor: 2.788

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.